Melbourne researchers step closer to defeating deadly sepsis

Sepsis is caused by the immune system going into over-drive in response to infection. It leads to extreme inflammation that can cause blood clots and block oxygen from reaching vital organs, resulting in tissue death and multiple organ failure. Some people who survive will need to have limbs amputated and be left with lifelong disability. It is commonly described as a silent disease because it's often misdiagnosed as the flu.

Researchers from La Trobe University in Melbourne have identified and characterised the gene responsible for immune cell death and inflammation during sepsis.

Their findings, reveal the removal of protein receptor TREML4 in cell based and in-vivo experiments leads to almost absolute protection from sepsis, sepsis-induced pneumonia and blood-born Candida infection commonly associated with invasive medical procedures.

Lead researcher Christina Nedeva, from the La Trobe Institute for Molecular Science, said sepsis is characterised by two deadly stages.

"The initial inflammatory phase, or septic shock, is followed by a prolonged immunosuppression phase, which commonly leads to pneumonia. While the shock accounts for about 15 per cent of sepsis-related deaths, the immunosuppression phase accounts for 85 per cent," Dr Nedeva said.

"Excitingly, we've discovered the TREML4 gene regulates both of these phases."

Lead supervisor of the study, La Trobe Associate Professor Hamsa Puthalakath, said current therapies aimed at controlling inflammation such as the use of steroids, help reduce the time that sepsis patients spend in intensive care units, but do not reduce the overall deaths.

"Steroids reduce inflammation, but they also wipe out the immune system, preventing our body from fighting both mild and serious infections," Associate Professor Puthalakath said.

"The removal of TREML4 can be described as the 'Goldilocks' approach, in that it leaves the body with some inflammation, but the immune system remains uncompromised and is healthy enough to fight off infection."

The researchers have already identified the human equivalents of the TREML4 receptor.

"There have been more than 100 clinical trials for sepsis-related therapies in the last 25 years, none of which have proved successful," Associate Professor Puthalakath said.

"La Trobe is on the forefront of potentially life-saving research. We hope to secure new funding for the next stage of our study, which will focus on the development of therapeutic antibodies against the TREML4 receptor."

Symptoms of sepsis include, but are not limited to:

The research has been published in Nature Immunology

Read more: Do you know the warning signs of deadly sepsis?

Read more: Palli8 plan proposes eight key recommendations to improve palliative care in aged care